Overview
IVVD market data
Price History
IVVD price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.30 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.95 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -138.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.48 – $3.07 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $198.3M · P/B 2.83 · P/S 3.55.
Company News
Invivyd Q2 EPS $(0.14) Misses $(0.11) Estimate, Sales $14.285M Miss $14.400M EstimateBenzinga · Aug 13, 2026, 8:25 PM
8-K filing — Invivyd, Inc. (IVVD)SEC EDGAR · Aug 13, 2026, 8:11 PM
The FDA Sent Invivyd An Advance Termination Notice For Pemgarda (Pemivibart) Emergency Use Authorization Following US Department Of Health And Human Services’ Announcement Of Advanced Notice Of Termination Of Covid-19 EUA Declaration On June 30, With Effective Date Of June 29, 2027Benzinga · Jul 6, 2026, 11:15 AM
Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026Benzinga · Jun 16, 2026, 11:20 AM
BTIG Reiterates Buy on Invivyd, Maintains $10 Price TargetBenzinga · Jun 9, 2026, 4:55 PM
Invivyd Dosed The First Participants In LIBERTY Phase 3 Trial Of VYD2311 Alone, And VYD2311 Co-administered With A Covid-19 Vaccine In Healthy Adults; Topline Data Is Expected In Q3 2026, To Accompany Anticipated Data From Pivotal DECLARATION StudyBenzinga · Jun 9, 2026, 11:10 AM
Invivyd Completes Enrollment In DECLARATION Phase 3 Trial of VYD2311 To Prevent Symptomatic Covid-19; Top-line Data Expected In Approximately Late Q3 2026Benzinga · Jun 1, 2026, 11:08 AM
Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On FridayBenzinga · May 15, 2026, 2:15 PM